NZ Rheumatology Research Review Issue 39

In this issue:

Cannabis-based medicinal products for arthritic pain
Targeted therapy tapering and infection risk/adverse events in RA/spondyloarthritis
Characteristics of patients with rheumatic disease hospitalised for COVID-19
2020 ACR guidelines for gout
Haematological abnormalities in new-onset RA and common infection risk
Physical therapy vs. glucocorticoid injections for knee OA
Adverse events with oral NSAIDs in knee OA
Pharmacological treatment of PsA
Therapeutic drug monitoring of adalimumab in RA
Secukinumab vs. adalimumab for PsA

Please login below to download this issue (PDF)